 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atossa Therapeutics Inc (ATOS) Reports Increased Operating Expenses and Advances in Clinical TrialsRelated Stocks: ATOS...

Atossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive Analysis

Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase 2 EVANGELINE study...

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Atossa Therapeutics provides five-year (Z)-endoxifen update

SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human...

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), today announced that on March 15, 2024, the Company received written notice from...

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ( Atossa or the Company ), a clinical stage biopharmaceutical company developing innovative medicines in areas...

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic (PK) run-in cohort of the ongoing Phase 2 EVANGELINE...

Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trial...

Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trial

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

Atossa Therapeutics' 'standalone and superior drug' Z-endoxifen for breast cancer seen boosting shares by 300...

Atossa Therapeutics' 'standalone and superior drug' Z-endoxifen for breast cancer seen boosting shares by 300%

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Volume (M)	2.32M
52-Wk High	$2.31
52-Wk Low	$0.5901

ATOS Atossa Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals